Fintini D, Grugni G, Bocchini S, Brufani C, Di Candia S, Corrias A, Delvecchio M, Salvatoni A, Ragusa L, Greggio N, Franzese A, Scarano E, Trifirò G, Mazzanti L, Chiumello G, Cappa M, Crinò A
Autoimmune Endocrine Diseases Unit, Bambino Gesù Children's Hospital, Research Institute, Rome, Italy.
Division of Auxology, Italian Auxological Institute, Research Institute, Piancavallo, Verbania, Italy.
Nutr Metab Cardiovasc Dis. 2016 Sep;26(9):842-7. doi: 10.1016/j.numecd.2016.05.010. Epub 2016 Jun 3.
Prader-Willi syndrome (PWS) is characterized by a high incidence of altered glucose metabolism (AGM). However, epidemiological data on impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM) are still discordant.
We performed a multicenter study based on 274 PWS patients [144 females, aged 20.3 ± 10.4 yrs (range: 8.1-50.1 years)] evaluating the prevalence for AGM in the entire group, and according to age (children <10 yrs; adolescents 10-18 yrs, and adults >18 yrs), Body Mass Index (BMI = kg/m(2)), gender, genotypes (deletion or uniparental disomy for chromosome 15), and GH therapy (GHT) (untreated, previously or currently treated). Altogether, AGM was detected in 67 (24.4%) of patients (0.7% IFG, 10.2% IGT, 13.5% T2DM). The prevalence of AGM was correlated to age (p = 0.001), BMI (p = 0.001) and HOMA-IR (p = 0.001). However, gender, genotype, and GHT did not influence AGM development in univariate analysis. These data were confirmed as positive predictors when inserted in a multivariate analysis model.
This study is the first report on the prevalence of AGM in a large population of PWS. Overall, PWS subjects show a high prevalence of AGM that appears more common in obese and adult subjects. Our data confirm the main role of obesity on the individual metabolic risk clustering in PWS, and thus reinforce the concept that improvement in weight control remains the most important goal of any PWS treatment program.
普拉德-威利综合征(PWS)的特征是糖代谢改变(AGM)的发生率较高。然而,关于空腹血糖受损(IFG)、糖耐量受损(IGT)和2型糖尿病(T2DM)的流行病学数据仍不一致。
我们对274例PWS患者[144例女性,年龄20.3±10.4岁(范围:8.1 - 50.1岁)]进行了一项多中心研究,评估了整个队列中AGM的患病率,并根据年龄(<10岁儿童;10 - 18岁青少年,以及>18岁成年人)、体重指数(BMI = kg/m²)、性别、基因型(15号染色体缺失或单亲二体)和生长激素治疗(GHT)(未治疗、既往或目前接受治疗)进行分析。总共在67例(24.4%)患者中检测到AGM(0.7%为IFG,10.2%为IGT,13.5%为T2DM)。AGM的患病率与年龄(p = 0.001)、BMI(p = 0.001)和HOMA-IR(p = 0.001)相关。然而,在单因素分析中,性别、基因型和GHT并未影响AGM的发生。当将这些数据纳入多因素分析模型时,被确认为阳性预测因子。
本研究是关于大量PWS患者中AGM患病率情况的首份报告。总体而言,PWS患者中AGM的患病率较高,在肥胖和成年患者中似乎更为常见。我们的数据证实了肥胖在PWS个体代谢风险聚集方面的主要作用,从而强化了体重控制改善仍然是任何PWS治疗方案最重要目标的这一概念。